Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. .TMU Publications / 北醫出版品(教師升等著作 / 教學實踐 / 學位論文)
  3. .博碩士學位論文
  4. .95學年度
  5. 微生物轉換isosteviol
 
  • Details
Options

微生物轉換isosteviol

Other Title
Microbial Transformations of Isosteviol
Type
thesis
Date Issued
2007-06-14
Author(s)
羅嘉欣
Advisor
林淑娟
Subjects
系所名稱:藥學研究所
Description
學位別:碩士
語文別:中文
指導教授:林淑娟
共同指導教授:
口試委員:陳國棟;張淑芬
中文關鍵字:甜菊
Abstract
Stevioside (1) 可由菊科植物甜菊(Stevia rebaudiana (Bertoni) Bertoni (Compositae) 葉片中萃取而得,一般作為甜味劑,目前在日本及巴西等地區被廣泛的當成代糖使用。Isosteviol (2; ent-16-ketobeyeran-19-oic acid) 為stevioside經由酸水解後所得之四環二萜類,屬於ent-beyerane結構的化合物。研究報告顯示其具有抑制liver mitochondria function,降低glucose 產生及抑制oxygen uptake,抑制 D-glucose 及 D-fructose 穿透細胞膜,抑制腫瘤生長,在動物實驗中,藉由打開自發性高血壓老鼠身上鉀離子管道來抑制鈣離子回流,使血壓降低,預防缺血再灌流對心臟的傷害及降低糖尿病老鼠之血糖等作用。為了取得更多的四環二萜類衍生物以進行生物活性試驗及其機轉探討,因此選擇isosteviol (2)為受質進行微生物轉換。
經過30株菌種篩選isosteviol (2),選擇Mucor recurvatus、Absidia pseudocylindrospora及 Aspergillus niger進行大量發酵培養,再經由抽取、分離及純化,由Mucor recurvatus得到ent-7a-hydroxy- 16-ketobeyeran-19-oic acid (3), ent-7b-hydroxy-16-ketobeyeran-19-oic acid (4), ent-12a,15a-dihydroxy-16-ketobeyeran-19-oic acid (5), ent-7a, 15a-dihydroxy-16-ketobeyeran-19-oic acid (6) 以及ent-15a-hydroxy- 16-ketobeyeran-19-oic acid (7);從Absidia pseudo- cylindrospora得到ent-12a,17-dihydroxy-16-ketobeyeran-19-oic acid (8), ent-9a,17-di- hydroxy-16-ketobeyeran-19-oic acid (9), ent-12b,17-dihydroxy-16- ketobeyeran-19-oic acid (10), ent-7b,12a-dihydroxy-16-ketobeyeran-19- oic acid (11), ent-7b,17-dihydroxy-16-ketobeyeran-19-oic acid (12) 以及 ent-7b,12a,17-trihydroxy-16-ketobeyeran-19-oic acid (13);從Aspergillus niger得到化合物3、ent-1b-hydroxy-16-ketobeyeran-19-oic acid (14), ent-1b,7a-dihydroxy-16-ketobeyeran-19-oic acid (15), ent-7a, 11a-dihydroxy-16-ketobeyeran-19-oic acid (16), ent-7a-hydroxy-1,16- diketobeyeran-19-oic acid (17), ent-1b-hydroxy-7,16-diketobeyeran- 19-oic acid (18), ent-11a-hydroxy-7,16-diketobeyeran-19-oic acid (19)以及ent-1b,6b,7a-trihydroxy-16-ketobeyeran-19-oic acid (20),其中化合物7、11、13、14及16-20為新化合物,所得化合物均經由低解析、高解析質譜、紅外線光譜及一維、二維核磁共振光譜等鑑定其結構。由於四環二萜類化合物與類固醇結構類似,因此接著將isosteviol (2)及所得代謝物(2-19)進行GRE (glucocorticoid-responsive element)及ARE (androgen-responsive element)-mediated luciferase reporter gene assays之生物活性試驗,經由GRE-mediated luciferase reporter gene assay篩選,發現化合物9、14、16及18均呈現有意義結果,但活性比methylprednisolone及dexamethasone弱;另經由ARE-mediated luciferase reporter gene assay篩選,發現化合物4、7、13、14、15及16均呈現有意義結果,尤其4、13、15及16的活性比testosterone強,未來將進一步探討有效化合物的作用機轉。
URI
https://203.71.86.71/handle/123456789/12217
https://hdl.handle.net/11296/ufh44m
File(s)
No Thumbnail Available
Name

C0183256.pdf

Size

13.73 MB

Format

Adobe PDF

Checksum

(MD5):edb198b355d7b5dcb046f2bedb5af9e5

Copyright Notice

● The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use.

● Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner. Users must not use TMUIR for any illegal purposes.

● By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in this statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions.

● TMUIR is committed to protecting the interests of copyright owners. If you believe that any material on this website infringes copyright, please contact our staff at libirtmu@gmail.com, and we will remove the work from the repository.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback